Crist, W., Gehan, E.A., Ragab, A.H., Dickman, P.S., Donaldson, S.S., Fryer, C., Hammond, D., Hays, D.M., Herrmann, J., Heyn, R., et al. (1995) The Third Intergroup Rhabdomyosarcoma Study. Journal of Clinical Oncology, 13, 610-630.
https://doi.org/10.1200/JCO.1995.13.3.610

has been cited by the following article:

• TITLE: Pediatric Nasopharyngeal Rhabdomyosarcoma: About a Case and Review of Literature

  AUTHORS: Dohoué Patricia Eliane Agbanglanon, Imane M’barki, Oswald Houessou, Gaël Kietga, Siham Jaba, Hafsa Elouazzani, Séka Evrard Narcisse, Hanan Elkacemi, Nadia Cherradi, Sanaa Elmajjaoui, Noureddine Benjaafar

  KEYWORDS: Rhabdomyosarcoma, Nasopharyngeal, Pediatric, Chemotherapy, Radiotherapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.12 No.1, January 14, 2021

  ABSTRACT: Introduction:Rhabdomyosarcoma (RMS) is the most common soft tissue tumor in children, with the head and neck location accounting for up to 40% of cases. The embryonal and alveolar histologic variants are more commonly seen in pediatric patients. The treatment is multimodal and the prognosis of this clinical entity is always gloomy. We report the case of nasopharyngeal rhabdomyosarcoma in a 7-year-old boy child with a good response to early post-therapy. Case Presentation: The patient was diagnosed with nasopharyngeal RMS revealed by a congested nose, ptosis and bilateral blindness, and who received induction chemotherapy followed by concurrent radiotherapy followed by adjuvant chemotherapy. The evolution is marked by a good clinical course but persistence of bilateral blindness. Conclusion: The RMS nasopharyngeal often presents with nonspecific symptoms. Multimodal therapy should be performed including surgery, chemotherapy and radiotherapy.